Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
271 hedge funds and large institutions have $1.5B invested in Catalyst Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 92 increasing their positions, 89 reducing their positions, and 31 closing their positions.
16% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 31
3% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 89
1% more funds holding
Funds holding: 269 → 271 (+2)
0.38% more ownership
Funds ownership: 81.68% → 82.06% (+0.38%)
2% less capital invested
Capital invested by funds: $1.53B → $1.5B (-$32.6M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
34% less call options, than puts
Call options by funds: $522K | Put options by funds: $789K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$46.2M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$35M |
| 3 |
BlackRock
New York
|
+$15M |
| 4 |
Renaissance Technologies
New York
|
+$4.47M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$4.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$33M |
| 2 |
Morgan Stanley
New York
|
-$12.2M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$8.57M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.34M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$7.23M |
CPRX Hedge Fund Activity: Q2 2024 in Review
271 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2024, worth a combined $1.5B — down 2.1% from $1.53B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CPRX positions and 31 closed out — a net gain of 5 holders — while 92 added to existing stakes and 89 trimmed.
The largest buyer was Pacer Advisors, adding an estimated $46.2M. The largest seller was State Street, cutting an estimated $33M.
- 271 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2024, up from 269 in Q1 2024.
- Funds reported $1.5B of Catalyst Pharmaceutical stock for Q2 2024, down 2.1% quarter-over-quarter.
- 36 funds opened new Catalyst Pharmaceutical positions in Q2 2024 and 31 closed out, a net change of +5 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2024 was Pacer Advisors, an estimated $46.2M added.
- The largest Catalyst Pharmaceutical seller in Q2 2024 was State Street, an estimated $33M sold.
Based on aggregated 13F filings for Q2 2024.